本帖最后由 老马 于 2012-1-13 21:20 编辑
; M0 N. u' D5 x r* W7 z4 Q
/ u( c' Z1 z8 k2 J6 H7 o3 u爱必妥和阿瓦斯丁的比较
1 C3 Q8 X* C% h o% p7 D
5 Q% y& e; z% ]6 C: shttp://cancergrace.org/lung/2008/08/30/bms099-os-neg/; G! k' \/ k" k
. |. t# _' o2 O0 Y3 q3 N: K2 B
, ]2 P0 A1 R% @6 o& ]( E
http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/3 F* b: y; N! i2 H2 x+ ?
==================================================; {' \3 g) t( C; K! ]( d' S) A0 z
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)8 A' d% C8 U% N7 y" X1 W( e+ s
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
/ p* p1 V+ t7 H" X5 A2 V/ FResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.4 A% G3 k4 ], Z! z, I6 T% Q
|